Identification and Quantification of the Angiofibrotic Switch in Neovascular AMD

Abstract

SHRM volume decreases significantly under anti-VEGF therapy. However, lesions unresponsive to therapy may progress to fibrosis as early as 3 months. Reduction in SHRM thickness may be a prognostic marker for treatment response.